It is a patient-customized treatment using individual immune cells, and a new form of treatment that can be Administered concurrently with chemical therapeutics and shows very low toxicity and side effects. Dendritic cells (DCs) are a principal antigen-presenting cell that acts as a commander of human immunity. They Present the antigen information to T cells and educate them to induce antigen specific T cell immune responses. If these cells fail to function normally, they will develop autoimmune diseases, cancers, and infectious diseases DC vaccine consists of dendritic cells generated from patient’s own monocytes in specialized generation method of JW CreaGene (patent No.: KR 10-1518972). When well trained DCs are injected into the patient, they move to lymph node, educate T cells to recognize cancer cells, and induce activation and proliferation of T cells. Finally, the activated T cells leave to blood to find, meet, and kill cancer cells. And released antigens from dying cancer cells can induce secondary immune responses. Furthermore, DC vaccinations induce memory T cells and these T cells help to prevent cancer recurrence.

CTP is a drug delivery technology that effectively transfers macromolecules to the cytoplasm. CTP is very useful as a drug delivery system that allows biologically active medicine to work in the cytoplasm. Drugs that are fused to CTP can exhibit effective results even at low concentrations due to improved cell membrane permeability.
In particular, when a recombinant protein fused with CTP is used as a cancer antigen, it exhibits a high antigen-sensitizing effect on dendritic cells, which can kill tumor cells by activating Cytotoxic T cells.